BioSig Awarded U.S. Patent Claims for its NeuroClear™ Subsidiary
March 04 2021 - 9:15AM
- The
patent is exclusively licensed from Mayo
Foundation for Medical Education and Research
-
Claims address methods and materials for
improving the treatment of hypertension
-
Fifteen additional licensed worldwide patent applications
are pending, generally covering electroporation and
stimulation
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that the U.S. Patent Office had allowed a
utility patent that its majority-owned subsidiary NeuroClear
Technologies, Inc. has exclusively licensed from the Mayo
Foundation for Medical Education and Research.
The recently allowed patent application number 16/805,017
entitled "Systems and Methods for Electroporation" was filed on
February 28, 2020. The patent describes and claims methods and
materials for improving the treatment of hypertension via
electroporation of nerves in the renal area. Electroporation is an
emerging technique that has demonstrated efficacy in treatments for
several critical conditions and is currently being evaluated for
the treatments of autonomic nervous disorders, including hyper- and
hypotension / syncope.
The allowed patent application complements BioSig’s expanding
patent portfolio, which now includes nine allowed/issued patents.
Sixteen additional worldwide utility patent applications are
pending covering various aspects of its PURE EP™ System for
recording, measuring, calculating, and displaying of
electrocardiograms during cardiac ablation procedures. The Company
has two additional pending U.S. patent applications directed to
artificial intelligence (AI). BioSig has 24 allowed/issued
worldwide design patents covering various features of its display
screens and graphical user interface for enhanced visualization of
biomedical signals. Finally, in addition to the patent
referenced above, BioSig has exclusive licenses to 15 additional
worldwide utility patent applications from Mayo Foundation for
Medical Education and Research that are pending. These 15
applications are generally directed to electroporation and
stimulation.
"We are pleased to announce this newest patent allowance which
creates a patent foundation for the development of our N-SENSE™
platform technology. Our first neurostimulation product aims to
address a vast market of neurological conditions through a
proprietary sensing design and algorithms tailored to specific
applications. Electroporation is a novel technique that has
significantly advanced cancer treatments and has shown promise in
treating cardiovascular disease. We look forward to exploring it
further with our research partners,” commented Kenneth L. Londoner,
Chairman, and CEO of BioSig Technologies, Inc.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve
signal fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP™ System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring, and calculating, displaying, recording, and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024